Clinical and bacteriological Effects of Synbiotic as an Adjunct in Phase I Periodontal Therapy

Phase 3

Conditions: Chronic periodontitis.
Chronic periodontitis
K05.3

Registration Number: IRCT20130216012487N7

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 28

Inclusion Criteria

Patient with complete physical and mental health
Who were not treated for periodontitis during the last two years
Who did not use probiotic food products during the past year
Who have at least 10 to 12 areas with the pocket depth of 3mm to 6 mm with bleeding on probing.

Exclusion Criteria

subjects with history of uncontrolled diabetes, AIDS, rheumatic fever, severe hepatic and renal problems, deficiency in immunological and neurological systems
patients consuming any type of medicine that affect periodontal tissue (Phenytoin, Cyclosporine and Nifedipine)
pregnant and lactating women
smokers and alcoholic subjects
subjects with a pocket depth of more than 6 mm

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Count of Porphyromonas gingivalis in subgingival plaque. Timepoint: At baseline and 30 days after intervention. Method of measurement: Dilution and culture of bactery samples in riched solid blood agar and black pigmentation of Porphyromonas gingivalis visual colony counting and microscopic experiments for detection of the gram negative bacillus of Porphyromonas gingivalis and biochemical tests.

Secondary Outcome Measures

Name	Time	Method
Measuring pocket depth. Timepoint: At baseline and 30 days after intervention. Method of measurement: Measuring of pocket depth in mm by a University of Michigan probe with Wiliams markings.;Measuring clinical attachment loss. Timepoint: At baseline and 30 days after intervention. Method of measurement: Measuring of clinical attachment loss in mm by University of Michigan with Wiliams markings probe.;Evaluation of bleeding on probing. Timepoint: At baseline and 30 days after intervention. Method of measurement: Probing by University of Michigan with Wiliams markings probe and then clinical absevation.